ClinicalTrials.gg
CompletedNCT03580655Updated Oct 20, 2026Results posted

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

A Phase 2 interventional study of Avapritinib in Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis and Systemic Mastocytosis With an Associated Hematologic Neoplasm, sponsored by Blueprint Medicines Corporation. Completed at 32 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Primary conditionLeukemia, Mast-CellRegistry: Mastocytosis, SystemicReclassifiedWhy we changed it
Registry
Mastocytosis, Systemic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Mast-Cell
Why
  1. The study's listed conditions name Leukemia, Mast-Cell, a narrower term within Mastocytosis, Systemic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 2, Interventional, and Treatment

Updated Oct 20, 2026Posted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
107
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies in Leukemia, Mast-Cell with a site in United States — 4 open to participants now, 7 under way, none of them phase 3. Leukemia, Mast-Cell · United States.

Enrollment
9th of 34
107 · median 45
Started
2018
the only one that year
Phase 2
14 of 48
2 open now
Registered
42nd of 48
by date
Lead sponsor
5 of 48
Blueprint Medicines Corporation

Among the 48 studies in Leukemia, Mast-Cell with a site in United States, this one is the 9th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2018, is one of 14 in phase 2, and was the 42nd registered.

Leukemia, Mast-Cell

60 studies on the registry are indexed under Leukemia, Mast-Cell; 5 are open to participants now.

Browse Leukemia, Mast-Cell studies →

Open to participants now

4 of the 48 studies in Leukemia, Mast-Cell with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Leukemia, Mast-Cell studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Leukemia, Mast-Cell with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)

03

Conditions studied

  • Advanced Systemic Mastocytosis
  • Aggressive Systemic Mastocytosis
  • Systemic Mastocytosis With an Associated Hematologic Neoplasm
  • Mast Cell Leukemia

Browse trials for

04

In context

Leukemia, Mast-Cell Reclassified

60 studies on the registry are indexed under Leukemia, Mast-Cell; 5 are open to participants now.

This study's enrollment of 107 is above the median of 50 across 38 interventional studies indexed under Leukemia, Mast-Cell.

Browse Leukemia, Mast-Cell studies →

Lead sponsor

Blueprint Medicines Corporation is the lead sponsor of 32 studies on the registry; 6 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 3 (21%) have results posted.

First submitted before Blueprint Medicines Corporation became part of Sanofi.

Compared within Leukemia, Mast-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mastocytosis, Systemic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Patient must have a diagnosis of aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) or mast cell leukemia (MCL) based on World Health Organization diagnostic criteria. Before enrollment, the Study Steering Committee must confirm the diagnosis of AdvSM (based on Central Pathology Laboratory assessment of bone marrow).
  2. Patient must have a serum tryptase ≥ 20 ng/mL.
  3. Patient must have (ECOG) performance status (PS) of 0 to 3.

Key Exclusion Criteria:

  1. Patient has received prior treatment with avapritinib.
  2. Patient has received any cytoreductive therapy (including midostaurin and other TKIs, hydroxyurea, azacitidine) or an agent less than 14 days, and for cladribine, interferon alpha, pegylated interferon and any antibody therapy (eg, brentuximab vedotin) less than 28 days before obtaining screening BM for this study.
  3. Patient has eosinophilia and known positivity for the FIP1L1 PGDFRA fusion, unless the patient has demonstrated relapse or PD on prior imatinib therapy. Patients with eosinophilia (> 1.5 × 10\^9/L), who do not have a detectable KIT D816 mutation, must be tested for a PDGFRA fusion mutation by fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR).
  4. Patient has history of another primary that has been diagnosed or required therapy within 3 years before the first dose of study drug. The following are exempt from the 3-year limit: completely resected basal cell and squamous cell skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ of any site.
  5. Patient has a corrected using Fridericia's formula (QTcF) > 480 msec.
  6. Patient has a known risk or recent history (12 months before the first dose of study drug) of intracranial bleeding (eg, brain aneurysm, concomitant vitamin K antagonist use).
  7. count \< 50,000/μL (within 4 weeks of the first dose of study drug) or receiving platelet transfusion(s).
  8. (AST) or alanine aminotransferase (ALT) >3 x the (ULN); no restriction if due to suspected liver infiltration by mast cells.
  9. >1.5 × ULN; no restriction if due to suspected liver infiltration by mast cells or Gilbert's disease. (In the case of Gilbert's disease, a direct bilirubin >2 × ULN would be an exclusion.)
  10. Estimated (eGFR) \< 30 mL/min/1.73m2 or creatinine > 1.5 × ULN.
  11. Patient has a primary brain malignancy or to the brain.
  12. Patient has a history of a seizure disorder (eg, epilepsy) or requirement for antiseizure medication.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Avapritinib

    Avapritinib will be administered as an immediate release tablet, orally, continuously, in 28-day cycles

    Drug: Avapritinib

Interventions

  • Avapritinib tablet

    Also known as: BLU-285

07

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis (mIWG-MRT-ECNM) Response Criteria

    ORR was defined as the percentage of participants with a confirmed best response of complete remission (CR), complete remission with partial recovery of peripheral blood counts (CRh), partial remission (PR), or clinical improvement (CI) by mIWG-MRT-ECNM criteria. The mIWG-MRT-ECNM criteria were based on findings from bone marrow biopsy and aspirate, and peripheral blood smear; bone marrow cytogenetics; other extracutaneous tissue biopsies (when available); liver and spleen imaging; and other clinical and laboratory parameters.

    Time frame: Baseline through Month 65

Secondary outcomes

  1. Mean Change From Baseline in Advanced Systemic Mastocytosis-Symptom Assessment Form (AdvSM-SAF) Total Symptom Score (TTS)

    The AdvSM-SAF is a 10-item questionnaire that assesses eight symptoms specific to AdvSM. All eight symptoms are scored on a scale of 0 (absence of symptoms) to 10 (more severe symptoms) (up to 80 points maximum). Each symptom contributes to the TSS equally. The TSS was generated based on average scores for each 7-day period. An increase in score from 0 (no symptoms) to 80 (worst symptoms represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an electronic diary (eDiary). Each cycle is 28 days long.

    Time frame: Baseline up to Month 6 (Cycle 6, Day 1)

  2. ORR Based on mIWG-MRT-ECNM Response Criteria as Assessed by Local Investigator

    ORR was defined as the percentage of participants with a confirmed best response of CR, CRh, PR, or CI by mIWG-MRT-ECNM criteria. The mIWG-MRT-ECNM criteria were based on findings from bone marrow biopsy and aspirate, and peripheral blood smear; bone marrow cytogenetics; other extracutaneous tissue biopsies (when available); liver and spleen imaging; and other clinical and laboratory parameters.

    Time frame: Baseline through Month 19

  3. Time-to-Response (TTR)

    TTR was defined as the time from first dose to the time of initial evaluation of clinical improvement (CI) or better. Here, 'Overall Number of Participants Analyzed' signifies those participants with a confirmed best response of CR, CRh, PR, and CI by mIWG-MRT-ECNM criteria.

    Time frame: Baseline through Month 65

  4. Duration of Response (DOR)

    DOR was defined as the time from initial documentation of a CI or better to the time of initial documentation of confirmed progressive disease (PD) or death due to any cause, whichever occurred first. For responders who had not progressed or died at the time of analysis, DOR was censored at the last response assessment that was stable disease (SD) or better. Here, 'Overall Number of Participants Analyzed' signifies those participants with a confirmed best response of CR, CRh, PR, and CI by mIWG-MRT-ECNM criteria.

    Time frame: Baseline through Month 65

  5. Progression-free Survival (PFS)

    PFS was defined as time from first dose to the time of initial documentation of confirmed PD or death due to any cause, whichever occurred first. Participants who had not progressed or died at the time of analysis were censored at the last response assessment that was SD or better.

    Time frame: Baseline through Month 65

  6. Overall Survival (OS)

    OS was defined as time from first dose to the time of death due to any cause. Participants who were known to be alive or are lost to follow-up were censored at the last time point they were known to be alive.

    Time frame: Baseline through Month 65

  7. Objective Response Rate

    The objective response rate was defined as the number of participants with a confirmed best response of morphologic complete remission, morphologic complete remission with partial recovery of peripheral blood counts, or morphologic partial remission by pure pathologic response (PPR) criteria. The PPR criteria are a modification of the mIWG-MRT-ECNM criteria that define deep responses where direct measure of the disease burden determined the response and focus on objective changes (bone marrow mast cell burden, serum tryptase, and complete blood count).

    Time frame: Baseline through Month 65

  8. Clinical Benefit Rate

    The clinical benefit rate was defined as the percentage of participants with a confirmed best response of CR, CRh, PR, CI, and SD by mIWG-MRT-ECNM criteria.

    Time frame: Baseline through Month 65

  9. Percent Change From Baseline in Bone Marrow Mast Cells

    Bone marrow biopsies and aspirates and peripheral blood smears were obtained for systemic mastocytosis response assessment according to mIWG-MRT-ECNM criteria. Each cycle is 28 days long.

    Time frame: Baseline up to Month 65

  10. Percent Change From Baseline in Serum Tryptase

    Blood samples were collected to characterize the change in serum tryptase concentration during treatment with avapritinib. Each cycle is 28 days long.

    Time frame: Baseline up to Month 65

  11. Percent Change From Baseline in V-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Aspartate 816 Valine (KIT D816V) Mutation Burden

    Bone marrow aspirate and PB samples were collected to characterize the KIT D816V mutation allele fraction. Each cycle is 28 days long.

    Time frame: Baseline up to Month 65

  12. Percent Change From Baseline in Liver Volume by Imaging

    Assessment of liver volume was performed using serial imaging with magnetic resonance imaging (MRI). Response was defined as resolution of palpable hepatomegaly (CR). Each cycle is 28 days long.

    Time frame: Baseline up to Month 65

  13. Percent Change From Baseline in Spleen Volume by Imaging

    Assessment of spleen volume was performed using serial imaging with MRI. Response was defined as ≥35% reduction in spleen volume (PR) or resolution of palpable splenomegaly (CR). Each cycle is 28 days long.

    Time frame: Baseline up to Month 65

  14. Mean Change From Baseline in AdvSM-SAF Skin and Gastrointestinal Domain Scores at Month 10

    The AdvSM-SAF is a 10-item questionnaire that assesses symptoms and functional domains specific to AdvSM. Eight symptoms are scored on a scale of 0 to 10 for severity and 2 symptoms (vomiting and diarrhea) are scored for number of episodes. The skin domain is scored on a scale of 0-30, where 0 represents an absence of symptoms and 30 the most severe symptom experience. Similarly, the gastrointestinal domain is scored on a scale of 0-40, where 0 represents an absence of symptoms and 40 the most severe symptom experience. Skin and gastrointestinal domain scores were generated based on average scores for each 7-day period. An increase in score represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an eDiary.

    Time frame: Baseline, Month 10

  15. Mean Change From Baseline in AdvSM-SAF Individual Symptom Scores (Severity) at Month 10

    The AdvSM-SAF is a 10-item questionnaire that assesses symptoms and functional domains specific to AdvSM. Individual symptom scores are generated based on average scores for each 7-day period. Eight symptoms are scored on a scale of 0 to 10 for severity. An increase in score represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an eDiary.

    Time frame: Baseline, Month 10

  16. Mean Change From Baseline in AdvSM-SAF Individual Symptom Scores (Episodes) at Month 10

    The AdvSM-SAF is a 10-item questionnaire that assesses symptoms and functional domains specific to AdvSM. Individual symptom scores are generated based on average scores for each 7-day period. Two symptoms (vomiting and diarrhea) are scored for number of episodes. An increase in score represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an eDiary.

    Time frame: Baseline, Month 10

  17. Change From Baseline in Patient's Global Impression of Symptom Severity (PGIS)

    The PGIS is a single-item scale that assesses a participant's perception of disease symptoms at a point in time. Scores range from 0 to 4 points, with higher values representing worse symptom outcomes. It is widely used to evaluate a participant's overall sense of whether a treatment has been beneficial. Each cycle is 28 days long.

    Time frame: Baseline, Cycle 1, Day 15 and Day 1 of Cycle 2, Cycle 3, Cycle 5, Cycle 7, Cycle 9, Cycle 11, Cycle 14, and Cycle 17 (28 days/cycle)

  18. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    Quality of life was assessed using EORTC QLQ-C30, which is a 30-item questionnaire that includes 5 functional domains (physical, cognitive, role, emotional, and social) and a global health status scale. Twenty-eight questions are scored from 1 (not at all) to 4 (very much), while the other 2 are scored from 1 (very poor) to 7 (excellent). The calculated average is standardized using a linear transformation to a standardized scale of 0 to 100, with a decrease in score representing a decrease in quality of life. Each cycle is 28 days long.

    Time frame: Baseline, Cycle 1, Day 15 and Day 1 of Cycle 2, Cycle 3, Cycle 5, Cycle 7, Cycle 9, Cycle 11, Cycle 14, and Cycle 17 (28 days/cycle)

  19. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAE)

    A TEAE was defined as any adverse events that occurred between the first dose of a study drug through 30 days after the last dose of any study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Baseline through Month 65

  20. Maximum Plasma Concentration (Cmax) of a Single Dose of Avapritinib

    Blood samples were collected at specified timepoints. Results reported as nanograms/milliliter (ng/mL).

    Time frame: Day 1 of Cycle 1 (1 hour postdose) (28 days/cycle)

  21. Correlation Between TSS and Serum Tryptase

    The change in baseline for AdvSM-SAF TSS was correlated with the change in baseline for serum tryptase. Spearman correlation coefficients were performed with corresponding scatter plots on change from baseline.

    Time frame: Baseline, Month 10

08

Results

Posted Apr 24, 2026
Limitations and caveats
Compared to investigator-assessed response with its challenging interpretations of any differences in ORR by central adjudication, ORR by centrally adjudicated mIWG-MRT-ECNM criteria as assessed by the study steering committee is the most accurate and reliable evaluation of response to treatment in AdvSM.

Participant flow

The Avapritinib group (N=107) includes all participants treated at a starting dose of 200 milligrams (mg) once daily (N=105) and 2 participants treated at a starting dose of 100 mg once daily. One participant was treated at a starting dose of 100 mg per previous protocol amendment, and 1 participant was treated at a starting dose of 100 mg per principal investigator decision.

Participant flow — Overall Study
MilestoneAvapritinib (100 mg)Avapritinib (200 mg)
Started2105
Received at least 1 dose of study drug2105
Pure pathologic response-evaluable population2105
Response-evaluable population281
Completed00
Not completed2105
Withdrew: Disease progression01
Withdrew: Participant non-compliance02
Withdrew: Physician decision05
Withdrew: Intracranial hemorrhage01
Withdrew: Sponsor decision143
Withdrew: Withdrawal by subject019
Withdrew: Lost to follow-up01
Withdrew: Death133

Outcome measures

PrimaryOverall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis (mIWG-MRT-ECNM) Response Criteria

ORR was defined as the percentage of participants with a confirmed best response of complete remission (CR), complete remission with partial recovery of peripheral blood counts (CRh), partial remission (PR), or clinical improvement (CI) by mIWG-MRT-ECNM criteria. The mIWG-MRT-ECNM criteria were based on findings from bone marrow biopsy and aspirate, and peripheral blood smear; bone marrow cytogenetics; other extracutaneous tissue biopsies (when available); liver and spleen imaging; and other clinical and laboratory parameters.

Time frame:
Baseline through Month 65
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis (mIWG-MRT-ECNM) Response Criteria
Percentage of ParticipantsAvapritinib
Overall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis (mIWG-MRT-ECNM) Response Criteria73.5 (62.7 to 82.6)
Statistical analysis
  • Avapritinib · Wald Test · p = < 0.0001
SecondaryMean Change From Baseline in Advanced Systemic Mastocytosis-Symptom Assessment Form (AdvSM-SAF) Total Symptom Score (TTS)

The AdvSM-SAF is a 10-item questionnaire that assesses eight symptoms specific to AdvSM. All eight symptoms are scored on a scale of 0 (absence of symptoms) to 10 (more severe symptoms) (up to 80 points maximum). Each symptom contributes to the TSS equally. The TSS was generated based on average scores for each 7-day period. An increase in score from 0 (no symptoms) to 80 (worst symptoms represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an electronic diary (eDiary). Each cycle is 28 days long.

Time frame:
Baseline up to Month 6 (Cycle 6, Day 1)
Reported as:
Mean · Score on a Scale
Mean Change From Baseline in Advanced Systemic Mastocytosis-Symptom Assessment Form (AdvSM-SAF) Total Symptom Score (TTS)
Score on a ScaleAvapritinib
Mean Change From Baseline in Advanced Systemic Mastocytosis-Symptom Assessment Form (AdvSM-SAF) Total Symptom Score (TTS)-6.40 ± 9.158
SecondaryORR Based on mIWG-MRT-ECNM Response Criteria as Assessed by Local Investigator

ORR was defined as the percentage of participants with a confirmed best response of CR, CRh, PR, or CI by mIWG-MRT-ECNM criteria. The mIWG-MRT-ECNM criteria were based on findings from bone marrow biopsy and aspirate, and peripheral blood smear; bone marrow cytogenetics; other extracutaneous tissue biopsies (when available); liver and spleen imaging; and other clinical and laboratory parameters.

Time frame:
Baseline through Month 19
Reported as:
Number · Percentage of Participants
ORR Based on mIWG-MRT-ECNM Response Criteria as Assessed by Local Investigator
Percentage of ParticipantsAvapritinib
ORR Based on mIWG-MRT-ECNM Response Criteria as Assessed by Local Investigator53.1 (34.7 to 70.9)
SecondaryTime-to-Response (TTR)

TTR was defined as the time from first dose to the time of initial evaluation of clinical improvement (CI) or better. Here, 'Overall Number of Participants Analyzed' signifies those participants with a confirmed best response of CR, CRh, PR, and CI by mIWG-MRT-ECNM criteria.

Time frame:
Baseline through Month 65
Reported as:
Median · Months
Time-to-Response (TTR)
MonthsAvapritinib
Time-to-Response (TTR)2.30 (0.3 to 20.3)
SecondaryDuration of Response (DOR)

DOR was defined as the time from initial documentation of a CI or better to the time of initial documentation of confirmed progressive disease (PD) or death due to any cause, whichever occurred first. For responders who had not progressed or died at the time of analysis, DOR was censored at the last response assessment that was stable disease (SD) or better. Here, 'Overall Number of Participants Analyzed' signifies those participants with a confirmed best response of CR, CRh, PR, and CI by mIWG-MRT-ECNM criteria.

Time frame:
Baseline through Month 65
Reported as:
Median · Months
Duration of Response (DOR)
MonthsAvapritinib
Duration of Response (DOR)57.8 (46.1 to NA)
SecondaryProgression-free Survival (PFS)

PFS was defined as time from first dose to the time of initial documentation of confirmed PD or death due to any cause, whichever occurred first. Participants who had not progressed or died at the time of analysis were censored at the last response assessment that was SD or better.

Time frame:
Baseline through Month 65
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsAvapritinib
Progression-free Survival (PFS)51.3 (38.7 to NA)
SecondaryOverall Survival (OS)

OS was defined as time from first dose to the time of death due to any cause. Participants who were known to be alive or are lost to follow-up were censored at the last time point they were known to be alive.

Time frame:
Baseline through Month 65
Reported as:
Median · Months
Overall Survival (OS)
MonthsAvapritinib
Overall Survival (OS)61.6 (60.0 to NA)
SecondaryObjective Response Rate

The objective response rate was defined as the number of participants with a confirmed best response of morphologic complete remission, morphologic complete remission with partial recovery of peripheral blood counts, or morphologic partial remission by pure pathologic response (PPR) criteria. The PPR criteria are a modification of the mIWG-MRT-ECNM criteria that define deep responses where direct measure of the disease burden determined the response and focus on objective changes (bone marrow mast cell burden, serum tryptase, and complete blood count).

Time frame:
Baseline through Month 65
Reported as:
Number · Percentage of Participants
Objective Response Rate
Percentage of ParticipantsAvapritinib
Objective Response Rate73.8 (64.4 to 81.9)
SecondaryClinical Benefit Rate

The clinical benefit rate was defined as the percentage of participants with a confirmed best response of CR, CRh, PR, CI, and SD by mIWG-MRT-ECNM criteria.

Time frame:
Baseline through Month 65
Reported as:
Number · Percentage of Participants
Clinical Benefit Rate
Percentage of ParticipantsAvapritinib
Clinical Benefit Rate89.2 (80.4 to 94.9)
SecondaryPercent Change From Baseline in Bone Marrow Mast Cells

Bone marrow biopsies and aspirates and peripheral blood smears were obtained for systemic mastocytosis response assessment according to mIWG-MRT-ECNM criteria. Each cycle is 28 days long.

Time frame:
Baseline up to Month 65
Reported as:
Mean · Percent Change
Percent Change From Baseline in Bone Marrow Mast Cells
Percent ChangeAvapritinib
Cycle 3, Day 1-63.74 ± 39.445
Cycle 7, Day 1-71.12 ± 35.602
Cycle 11, Day 1-73.10 ± 49.885
Cycle 17, Day 1-81.33 ± 32.377
Cycle 23, Day 1-80.84 ± 29.283
Cycle 29, Day 1-78.90 ± 29.181
Cycle 35, Day 1-83.53 ± 28.316
Cycle 41, Day 1-83.32 ± 21.374
Cycle 47, Day 1-81.38 ± 21.656
Cycle 53, Day 1-75.83 ± 29.094
Cycle 59, Day 1-79.55 ± 21.921
Cycle 65, Day 1-68.03 ± 26.781
SecondaryPercent Change From Baseline in Serum Tryptase

Blood samples were collected to characterize the change in serum tryptase concentration during treatment with avapritinib. Each cycle is 28 days long.

Time frame:
Baseline up to Month 65
Reported as:
Mean · Percent Change
Percent Change From Baseline in Serum Tryptase
Percent ChangeAvapritinib
Cycle 1, Day 15-64.54 ± 41.191
Cycle 2, Day 1-68.54 ± 42.091
Cycle 3, Day 1-71.76 ± 40.023
Cycle 7, Day 1-75.18 ± 45.822
Cycle 11, Day 1-78.69 ± 36.038
Cycle 17, Day 1-85.22 ± 26.070
Cycle 23, Day 1-85.61 ± 30.510
Cycle 29, Day 1-83.50 ± 40.716
Cycle 35, Day 1-83.39 ± 45.603
Cycle 41, Day 1-90.64 ± 14.206
Cycle 47, Day 1-90.64 ± 12.581
Cycle 53, Day 1-68.65 ± 85.482
Cycle 59, Day 1-92.23 ± 6.8211
Cycle 65, Day 1-82.01 ± 14.529
SecondaryPercent Change From Baseline in V-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Aspartate 816 Valine (KIT D816V) Mutation Burden

Bone marrow aspirate and PB samples were collected to characterize the KIT D816V mutation allele fraction. Each cycle is 28 days long.

Time frame:
Baseline up to Month 65
Reported as:
Mean · Percent Change
Percent Change From Baseline in V-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Aspartate 816 Valine (KIT D816V) Mutation Burden
Percent ChangeAvapritinib
Cycle 1, Day 15-14.65 ± 21.049
Cycle 2, Day 1-41.68 ± 23.171
Cycle 3, Day 1-54.32 ± 31.272
Cycle 7, Day 1-65.46 ± 32.953
Cycle 11, Day 1-67.77 ± 30.802
Cycle 17, Day 1-77.25 ± 26.783
Cycle 23, Day 1-77.09 ± 29.838
Cycle 29, Day 1-80.97 ± 29.775
Cycle 35, Day 1-81.93 ± 31.110
Cycle 41, Day 1-85.31 ± 24.911
Cycle 47, Day 1-81.76 ± 28.490
Cycle 53, Day 1-76.27 ± 34.561
Cycle 59, Day 1-64.42 ± 37.677
Cycle 65, Day 1-47.58 ± 47.893
SecondaryPercent Change From Baseline in Liver Volume by Imaging

Assessment of liver volume was performed using serial imaging with magnetic resonance imaging (MRI). Response was defined as resolution of palpable hepatomegaly (CR). Each cycle is 28 days long.

Time frame:
Baseline up to Month 65
Reported as:
Mean · Percent Change
Percent Change From Baseline in Liver Volume by Imaging
Percent ChangeAvapritinib
Cycle 3, Day 1-12.45 ± 10.103
Cycle 7, Day 1-18.53 ± 12.376
Cycle 11, Day 1-22.07 ± 11.603
Cycle 17, Day 1-27.92 ± 11.949
Cycle 23, Day 1-29.50 ± 12.983
Cycle 29, Day 1-29.84 ± 13.588
Cycle 35, Day 1-29.81 ± 16.764
Cycle 41, Day 1-31.77 ± 16.694
Cycle 47, Day 1-34.31 ± 13.973
Cycle 53, Day 1-35.86 ± 14.147
Cycle 59, Day 1-31.74 ± 18.020
Cycle 65, Day 1-26.88 ± 21.594
SecondaryPercent Change From Baseline in Spleen Volume by Imaging

Assessment of spleen volume was performed using serial imaging with MRI. Response was defined as ≥35% reduction in spleen volume (PR) or resolution of palpable splenomegaly (CR). Each cycle is 28 days long.

Time frame:
Baseline up to Month 65
Reported as:
Mean · Percent Change
Percent Change From Baseline in Spleen Volume by Imaging
Percent ChangeAvapritinib
Cycle 3, Day 1-28.47 ± 26.817
Cycle 7, Day 1-35.77 ± 26.770
Cycle 11, Day 1-38.71 ± 28.700
Cycle 17, Day 1-47.53 ± 23.957
Cycle 23, Day 1-44.89 ± 24.377
Cycle 29, Day 1-44.30 ± 32.952
Cycle 35, Day 1-45.00 ± 32.274
Cycle 41, Day 1-51.33 ± 25.812
Cycle 47, Day 1-52.45 ± 24.580
Cycle 53, Day 1-42.85 ± 45.498
Cycle 59, Day 1-40.35 ± 28.396
Cycle 65, Day 1-40.27 ± 11.884
SecondaryMean Change From Baseline in AdvSM-SAF Skin and Gastrointestinal Domain Scores at Month 10

The AdvSM-SAF is a 10-item questionnaire that assesses symptoms and functional domains specific to AdvSM. Eight symptoms are scored on a scale of 0 to 10 for severity and 2 symptoms (vomiting and diarrhea) are scored for number of episodes. The skin domain is scored on a scale of 0-30, where 0 represents an absence of symptoms and 30 the most severe symptom experience. Similarly, the gastrointestinal domain is scored on a scale of 0-40, where 0 represents an absence of symptoms and 40 the most severe symptom experience. Skin and gastrointestinal domain scores were generated based on average scores for each 7-day period. An increase in score represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an eDiary.

Time frame:
Baseline, Month 10
Reported as:
Mean · Score on a Scale
Mean Change From Baseline in AdvSM-SAF Skin and Gastrointestinal Domain Scores at Month 10
Score on a ScaleAvapritinib
Skin Domain-2.52 ± 5.362
Gastrointestinal Domain-2.81 ± 5.172
SecondaryMean Change From Baseline in AdvSM-SAF Individual Symptom Scores (Severity) at Month 10

The AdvSM-SAF is a 10-item questionnaire that assesses symptoms and functional domains specific to AdvSM. Individual symptom scores are generated based on average scores for each 7-day period. Eight symptoms are scored on a scale of 0 to 10 for severity. An increase in score represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an eDiary.

Time frame:
Baseline, Month 10
Reported as:
Mean · Score on a Scale
Mean Change From Baseline in AdvSM-SAF Individual Symptom Scores (Severity) at Month 10
Score on a ScaleAvapritinib
Fatigue-1.12 ± 2.836
Spots-0.80 ± 2.099
Itching-0.94 ± 2.302
Flushing-0.78 ± 2.351
Abdominal Pain-1.51 ± 2.439
Nausea-0.75 ± 1.723
Vomiting-0.03 ± 1.004
Diarrhea-0.53 ± 1.970
SecondaryMean Change From Baseline in AdvSM-SAF Individual Symptom Scores (Episodes) at Month 10

The AdvSM-SAF is a 10-item questionnaire that assesses symptoms and functional domains specific to AdvSM. Individual symptom scores are generated based on average scores for each 7-day period. Two symptoms (vomiting and diarrhea) are scored for number of episodes. An increase in score represents a worse symptoms outcome. Participants completed the AdvSM-SAF daily using an eDiary.

Time frame:
Baseline, Month 10
Reported as:
Mean · Number of Episodes
Mean Change From Baseline in AdvSM-SAF Individual Symptom Scores (Episodes) at Month 10
Number of EpisodesAvapritinib
Vomiting0.31 ± 2.642
Diarrhea-0.30 ± 2.302
SecondaryChange From Baseline in Patient's Global Impression of Symptom Severity (PGIS)

The PGIS is a single-item scale that assesses a participant's perception of disease symptoms at a point in time. Scores range from 0 to 4 points, with higher values representing worse symptom outcomes. It is widely used to evaluate a participant's overall sense of whether a treatment has been beneficial. Each cycle is 28 days long.

Time frame:
Baseline, Cycle 1, Day 15 and Day 1 of Cycle 2, Cycle 3, Cycle 5, Cycle 7, Cycle 9, Cycle 11, Cycle 14, and Cycle 17 (28 days/cycle)
Reported as:
Mean · Score on a Scale
Change From Baseline in Patient's Global Impression of Symptom Severity (PGIS)
Score on a ScaleAvapritinib
Cycle 1, Day 15-0.7 ± 1.23
Cycle 2, Day 1-0.9 ± 1.24
Cycle 3, Day 1-1.0 ± 1.20
Cycle 5, Day 1-1.0 ± 1.32
Cycle 7, Day 1-1.1 ± 1.46
Cycle 9, Day 1-1.3 ± 1.50
Cycle 11, Day 1-1.3 ± 1.36
Cycle 14, Day 1-1.4 ± 1.65
Cycle 17, Day 1-1.5 ± 1.41
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

Quality of life was assessed using EORTC QLQ-C30, which is a 30-item questionnaire that includes 5 functional domains (physical, cognitive, role, emotional, and social) and a global health status scale. Twenty-eight questions are scored from 1 (not at all) to 4 (very much), while the other 2 are scored from 1 (very poor) to 7 (excellent). The calculated average is standardized using a linear transformation to a standardized scale of 0 to 100, with a decrease in score representing a decrease in quality of life. Each cycle is 28 days long.

Time frame:
Baseline, Cycle 1, Day 15 and Day 1 of Cycle 2, Cycle 3, Cycle 5, Cycle 7, Cycle 9, Cycle 11, Cycle 14, and Cycle 17 (28 days/cycle)
Reported as:
Mean · Score on a Scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Score on a ScaleAvapritinib
Cycle 1, Day 1514.66 ± 23.397
Cycle 2, Day 114.33 ± 24.855
Cycle 3, Day 115.00 ± 28.516
Cycle 5, Day 114.04 ± 30.042
Cycle 7, Day 115.85 ± 30.575
Cycle 9, Day 117.95 ± 29.801
Cycle 11, Day 118.78 ± 28.179
Cycle 14, Day 122.32 ± 31.346
Cycle 17, Day 121.49 ± 29.207
SecondaryNumber of Participants Experiencing Treatment-emergent Adverse Events (TEAE)

A TEAE was defined as any adverse events that occurred between the first dose of a study drug through 30 days after the last dose of any study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Baseline through Month 65
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAE)
ParticipantsAvapritinib
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAE)107
SecondaryMaximum Plasma Concentration (Cmax) of a Single Dose of Avapritinib

Blood samples were collected at specified timepoints. Results reported as nanograms/milliliter (ng/mL).

Time frame:
Day 1 of Cycle 1 (1 hour postdose) (28 days/cycle)
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of a Single Dose of Avapritinib
ng/mLAvapritinib
Maximum Plasma Concentration (Cmax) of a Single Dose of Avapritinib191 (191 to 191)
SecondaryCorrelation Between TSS and Serum Tryptase

The change in baseline for AdvSM-SAF TSS was correlated with the change in baseline for serum tryptase. Spearman correlation coefficients were performed with corresponding scatter plots on change from baseline.

Time frame:
Baseline, Month 10
Reported as:
Number · Spearman Coefficient
Correlation Between TSS and Serum Tryptase
Spearman CoefficientAvapritinib
Correlation Between TSS and Serum Tryptase0.1043

Adverse events

Collected over Day 1 through Month 65. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Avapritinib (100 mg)1/2 (50%)2/2 (100%)2/2 (100%)
Avapritinib (200 mg)33/105 (31.4%)67/105 (63.8%)104/105 (99%)
Most frequent serious events
Showing 10 of 135
Most frequent serious events
EventAvapritinib (100 mg)Avapritinib (200 mg)
Cardiac failureCardiac disorders1/23/105
Gastrointestinal haemorrhageGastrointestinal disorders1/23/105
AscitesGastrointestinal disorders1/21/105
Lymphangiectasia intestinalGastrointestinal disorders1/20/105
Herpes zosterInfections and infestations1/20/105
LymphangiectasiaVascular disorders1/20/105
COVID-19Infections and infestations0/24/105
PneumoniaInfections and infestations0/24/105
Cognitive disorderNervous system disorders0/24/105
NephrolithiasisRenal and urinary disorders0/24/105
Most frequent other events
Showing 10 of 94
Most frequent other events
EventAvapritinib (100 mg)Avapritinib (200 mg)
AnaemiaBlood and lymphatic system disorders2/254/105
DiarrhoeaGastrointestinal disorders2/236/105
FatigueGeneral disorders2/222/105
Night sweatsSkin and subcutaneous tissue disorders2/26/105
NeutropeniaBlood and lymphatic system disorders1/224/105
LeukopeniaBlood and lymphatic system disorders1/28/105
Periorbital oedemaEye disorders1/245/105
VomitingGastrointestinal disorders1/224/105
AscitesGastrointestinal disorders1/26/105
Abdominal pain upperGastrointestinal disorders1/25/105

Baseline characteristics

Safety Population: all participants who received at least 1 dose of avapritinib.

Age, Continuous
Age, Continuous(Years)Avapritinib
Mean67.1 ± 10.38
Sex: Female, Male
Sex: Female, Male(Participants)Avapritinib
Female45
Male62
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Avapritinib
Hispanic or Latino2
Not Hispanic or Latino91
Unknown or Not Reported14
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Avapritinib
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White91
More than one race0
Unknown or Not Reported15
09

Study locations

32 sites
  • Stanford Cancer Institute
    Stanford, California 94305, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • The University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14263, United States
  • Herbert Irving Comprehensive Cancer Center
    New York, New York 10032, United States
  • University of Pennsylvania, Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • University of Texas, MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Mays Cancer Center
    San Antonio, Texas 78229, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Medizinische Universität Wien, Universitätsklinik für Innere Medizin I, Klinische Abteilung für Hämatologie und Hämostaseologie
    Vienna, 1090, Austria
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • Odense University Hospital, Department of Haematology
    Odense, DK-5000, Denmark
  • Hôpital Necker-Enfants Malades
    Paris, 75015, France
  • CHU Toulouse - Hôpital Larrey
    Toulouse, 31059, France
  • Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltranslplantation
    Aachen, 52074, Germany
  • Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie
    Hamburg, 20246, Germany
  • Universitätsklinikum Leipzig, Medizinische Klinik und Poliklinik I - Hämatologie und Zelltherapie, lnternistische Onkologie, Hämostaseologie
    Leipzig, 04103, Germany
  • Universitätsmedizin Mannheim III. Medizinische Klinik
    Mannheim, 68167, Germany
  • Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der TU München
    Munich, 81675, Germany
  • Azienda Ospedaliero-Universitaria Careggi, CRIMM - Centro di Ricerca ed Innovazione per le Malattie Mieloproliferative
    Florence, 50134, Italy
  • A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno
    Salerno, 84131, Italy
  • Centro Ricerche Cliniche di Verona - Azienda Ospedaliera Universitaria Integrata di Verona
    Verona, 37134, Italy
  • University Medical Center Groningen (UMCG)
    Groningen, 9713 GZ, Netherlands
  • Oslo University Hospital-Rikshospitalet, Hematology
    Oslo, 0372, Norway
  • Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii
    Gdansk, 80-214, Poland
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu, Klinice Hematologii, Nowotworów Krwi i Transplantacji Szpiku
    Wroclaw, 50-367, Poland
  • lnstituto de Estudios de Mastocitosis de Castilla la Mancha, Hospital Virgen del Valle - Complejo Hospitalario de Toledo
    Toledo, 45071, Spain
  • Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde
    Glasgow, G12 0YN, United Kingdom
  • Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
    London, SE1 9RT, United Kingdom
10

References and documents

Publications

  • Gotlib J, Reiter A, Radia DH, Alvarez-Twose I, Deininger MW, George TI, Panse J, Mital A, Pettit KM, Vannucchi AM, Platzbecker U, Hermine O, Elshoury A, Livideanu CB, Mesa R, Ustun C, Triggiani M, Dybedal I, Jurcic JG, Zanotti R, Oh ST, Yacoub A, Hexner EO, Bose P, Lee SG, Sperr WR, Griffiths EA, Butler M, Lubke J, Bidollari I, Lin HM, Rylova S, Dimitrijevic S, Munoz-Gonzalez JI, DeAngelo DJ. Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study. Blood Adv. 2026 May 26;10(10):3676-3689. doi: 10.1182/bloodadvances.2025017519. PubMed 41604606 ↗
  • Reiter A, Gotlib J, Alvarez-Twose I, Radia DH, Lubke J, Bobbili PJ, Wang A, Norregaard C, Dimitrijevic S, Sullivan E, Louie-Gao M, Schwaab J, Galinsky IA, Perkins C, Sperr WR, Sriskandarajah P, Chin A, Sendhil SR, Duh MS, Valent P, DeAngelo DJ. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia. 2022 Aug;36(8):2108-2120. doi: 10.1038/s41375-022-01615-z. Epub 2022 Jul 5. PubMed 35790816 ↗
  • Reiter A, Schwaab J, DeAngelo DJ, Gotlib J, Deininger MW, Pettit KM, Alvarez-Twose I, Vannucchi AM, Panse J, Platzbecker U, Hermine O, Dybedal I, Lin HM, Rylova SN, Ehlert K, Dimitrijevic S, Radia DH. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Adv. 2022 Nov 8;6(21):5750-5762. doi: 10.1182/bloodadvances.2022007539. PubMed 35640224 ↗
  • Gotlib J, Reiter A, Radia DH, Deininger MW, George TI, Panse J, Vannucchi AM, Platzbecker U, Alvarez-Twose I, Mital A, Hermine O, Dybedal I, Hexner EO, Hicks LK, Span L, Mesa R, Bose P, Pettit KM, Heaney ML, Oh ST, Sen J, Lin HM, Mar BG, DeAngelo DJ. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021 Dec;27(12):2192-2199. doi: 10.1038/s41591-021-01539-8. Epub 2021 Dec 6. PubMed 34873345 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Dec 2024, 72 months.

Results were first posted in Apr 2026, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2018
First posted
Jul 9, 2018
StartActual
Nov 21, 2018
Primary completionActual
Dec 18, 2024
CompletionActual
Dec 18, 2024
Results first posted
Apr 24, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Posted results revised
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT03580655
Responsible party
Sponsor
First posted
Jul 9, 2018
Start date
Nov 21, 2018
Primary completion
Dec 18, 2024
Completion
Dec 18, 2024
Results posted
Apr 24, 2026
Last update
Oct 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avapritinib

Start the discussion